Cells,
Journal Year:
2024,
Volume and Issue:
13(22), P. 1862 - 1862
Published: Nov. 10, 2024
CD47
is
expressed
on
cell
surfaces
and
acts
as
a
"don't
eat
me"
signal
by
interacting
with
signal-regulatory
protein-α
the
macrophage
surface.
Some
cancer
cells
express
protein
can
evade
phagocytosis.
Herein,
we
evaluated
feasibility
of
targeting
for
osteosarcoma
analyzing
its
expression
patterns,
clinicopathological
correlations,
immunotherapeutic
potential.
We
performed
retrospective
analysis
24
biopsy
samples
from
patients
to
investigate
correlations
between
positivity
characteristics.
was
detected
in
20.8%
samples.
correlated
metastasis
at
diagnosis.
Patients
CD47-positive
tumors
were
older
than
those
CD47-negative
tumors.
However,
not
associated
sex,
tumor
size,
or
histologic
response
preoperative
chemotherapy.
In
vitro,
antibody
(B6H12)
did
affect
viability
apoptosis.
wound-healing
assay,
inhibited
migration
cells.
Differentiated
macrophages
exhibited
higher
phagocytic
activity
against
when
pretreated
B6H12
compared
isotype
control.
Our
preliminary
data
suggest
possible
interaction
phagocytosis
metastasis.
A
better
understanding
role
necessary
develop
an
innovative
approach
osteosarcoma.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics,
Journal Year:
2024,
Volume and Issue:
33(3), P. 519 - 531
Published: Nov. 6, 2024
Osteosarcoma
is
a
bone
malignancy
characterized
by
strong
invasiveness
and
rapid
disease
progression.
The
tumor
microenvironment
of
osteosarcoma
contains
various
types
immune
cells,
including
myeloid-derived
suppressor
macrophages,
T
B
cells.
Imbalances
these
cells
can
promote
the
proliferation
metastasis
osteosarcoma.
Recent
studies
have
indicated
substantial
increase
in
levels
an
cell
associated
with
immunosuppressive
pro-cancer
effects,
peripheral
blood
patients
Moreover,
pro-inflammatory
cytokine
interleukin
18
are
positively
correlated
those
animal
models
In
this
review,
we
explore
function
based
on
clinical
diagnoses
discuss
future
therapeutic
approaches
for
targeting
Targeting
represents
promising
approach
to
improving
prognosis
survival
rates
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics,
Journal Year:
2024,
Volume and Issue:
0(0), P. 1 - 10
Published: Jan. 1, 2024
Osteosarcoma
(OS)
is
a
prevalent
primary
bone
malignancy
with
limited
treatment
options.
Therefore,
it
imperative
to
investigate
and
understand
the
mechanisms
underlying
OS
pathogenesis.
Cancer-associated
fibroblasts
(CAFs)
are
markedly
abundant
in
tumor
stromal
cells
essentially
involved
modulation
of
occurrence
development.
In
recent
years,
CAFs
have
become
hotspot
as
researchers
aim
elucidate
CAF
that
regulate
progression.
However,
most
studies
on
few
common
cancers,
their
association
remains
elusive.
This
review
describes
role
current
knowledge
OS,
focusing
potential
cellular
origin,
classification,
diverse
functionality.
It
was
found
influenced
cell
signaling,
proliferation,
invasion,
metastasis,
epithelial-mesenchymal
transition,
stemness
maintenance,
angiogenesis,
ability
modify
immune
system
components.
Furthermore,
findings
other
cancers
indicated
effective
therapeutic
strategies
included
manipulation
activation,
targeting
CAF-derived
components,
depletion
by
biomarkers.
provides
new
insights
theoretical
basis
for
research.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Nov. 8, 2024
Osteosarcoma,
a
highly
aggressive
malignant
bone
tumor,
is
significantly
influenced
by
the
intricate
interactions
within
its
tumor
microenvironment
(TME),
particularly
involving
neutrophils.
This
review
delineates
multifaceted
roles
of
neutrophils,
including
tumor-associated
neutrophils
(TANs)
and
neutrophil
extracellular
traps
(NETs),
in
osteosarcoma’s
pathogenesis.
TANs
exhibit
both
pro-
anti-tumor
phenotypes,
modulating
growth
immune
evasion,
while
NETs
facilitate
cell
adhesion,
migration,
immunosuppression.
Clinically,
neutrophil-related
markers
such
as
neutrophil-to-lymphocyte
ratio
(NLR)
predict
patient
outcomes,
highlighting
potential
for
neutrophil-targeted
therapies.
Unraveling
these
complex
crucial
developing
novel
treatment
strategies
that
harness
TME
to
improve
osteosarcoma
management.
Cells,
Journal Year:
2024,
Volume and Issue:
13(22), P. 1862 - 1862
Published: Nov. 10, 2024
CD47
is
expressed
on
cell
surfaces
and
acts
as
a
"don't
eat
me"
signal
by
interacting
with
signal-regulatory
protein-α
the
macrophage
surface.
Some
cancer
cells
express
protein
can
evade
phagocytosis.
Herein,
we
evaluated
feasibility
of
targeting
for
osteosarcoma
analyzing
its
expression
patterns,
clinicopathological
correlations,
immunotherapeutic
potential.
We
performed
retrospective
analysis
24
biopsy
samples
from
patients
to
investigate
correlations
between
positivity
characteristics.
was
detected
in
20.8%
samples.
correlated
metastasis
at
diagnosis.
Patients
CD47-positive
tumors
were
older
than
those
CD47-negative
tumors.
However,
not
associated
sex,
tumor
size,
or
histologic
response
preoperative
chemotherapy.
In
vitro,
antibody
(B6H12)
did
affect
viability
apoptosis.
wound-healing
assay,
inhibited
migration
cells.
Differentiated
macrophages
exhibited
higher
phagocytic
activity
against
when
pretreated
B6H12
compared
isotype
control.
Our
preliminary
data
suggest
possible
interaction
phagocytosis
metastasis.
A
better
understanding
role
necessary
develop
an
innovative
approach
osteosarcoma.
